The virtual care app developer has added $8m of additional capital to its series B round backed by Northwell Ventures and UH Ventures.
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
The medical equipment maker is set to pay as much as $925m to buy its portfolio company that will enable Novo, Merck & Co and Samsung to exit.
UnitedHealth Group and Merck & Co are both in line for exits as Decipher Biosciences files for a $100m initial public offering.
Vera has picked up series C cash from investors including GV and Alexandria Venture Investments to help progress its Merck Group-licensed autoimmune disease drug candidate through clinical trials.
Amgen and Pfizer-backed oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.
Novo and Pfizer are among the investors set to exit the cancer therapy developer, which has set a $100m target for its initial public offering.
GV-backed Aledade has secured series D funding at a $2.2bn post-money valuation to build out the business model for its primary care network.
Lilly Asia Ventures is the largest shareholder of liver disease therapy developer Terns, which closed a $97.7m round earlier this month.
PureTech Health, Johnson & Johnson and Novartis are in line for exits after the cancer drug developer filed for its initial public offering.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
